Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Amgen (NASDAQ:AMGN) had its price target upped by research analysts at Royal Bank Of Canada from $335.00 to $360.00 in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s price target indicates a potential downside of 2.12% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Morgan Stanley cut their price target on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. HSBC reiterated a “buy” rating and set a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. DZ Bank raised their price objective on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. The Goldman Sachs Group upped their target price on Amgen from $400.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Finally, Scotiabank initiated coverage on Amgen in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $347.65.

Amgen Stock Up 0.4%

NASDAQ AMGN opened at $367.80 on Wednesday. Amgen has a 1 year low of $261.43 and a 1 year high of $374.90. The stock has a market capitalization of $198.05 billion, a PE ratio of 25.85, a PEG ratio of 3.20 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.99. The business’s 50-day moving average is $333.66 and its 200 day moving average is $310.84.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter last year, the business posted $5.31 EPS. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen will post 20.62 earnings per share for the current year.

Insider Activity at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last 90 days. Corporate insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

Several institutional investors have recently bought and sold shares of AMGN. Anfield Capital Management LLC grew its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC boosted its stake in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen during the 4th quarter valued at $26,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen in the second quarter worth $27,000. Finally, Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen in the second quarter worth $32,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates and management issued a robust 2026 outlook, driven by double‑digit revenue and EPS growth and strong new‑product uptake — a primary driver of the rally. Amgen Q4 results beat Street estimates
• Positive Sentiment: Several brokerages raised price targets (notably Goldman Sachs to $415 and RBC/Leerink upgrades), lending credibility to upside expectations and supporting institutional buying interest. Goldman Sachs adjusts price target on Amgen
• Positive Sentiment: Momentum indicators and flow show Amgen near 52‑week highs with reports of institutional accumulation, reinforcing sentiment that the company’s growth trajectory is being re‑rated. Amgen Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Amgen reported completion of postmarketing work on IMLYGIC’s melanoma safety study and updates on the FORTITUDE‑301 trial; these procedural milestones reduce uncertainty but are unlikely to move the needle until detailed data or regulatory actions follow. IMLYGIC safety study reaches completion
• Neutral Sentiment: Analyst coverage is mixed: some firms reiterate holds or lower relative targets even as others are bullish, creating a split narrative on valuation vs. execution risk. Analyst: new-product uptake offset by legacy erosion
• Negative Sentiment: CVS Health will remove Amgen and Lilly bone‑disease treatments from some preferred drug lists effective April 1, substituting lower‑cost alternatives — a clear near‑term sales headwind for affected products and a reason for investor caution. CVS to drop Amgen and Lilly bone disease treatments

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.